"I am glad that taking part in a trial might help others on their own cancer journey.”
A trial of blinatumomab for children and young people with a certain type of acute lymphoblastic leukaemia
This trial looked at a drug called blinatumomab for children and teenagers with a type of acute lymphoblastic leukaemia (ALL) called B cell precursor ALL.
More about this trial
Doctors usually treat acute lymphoblastic leukaemia (ALL) with chemotherapy and possibly a stem cell transplant. But sometimes these treatments don’t work or the leukaemia comes back after treatment.
Researchers wanted to find out if blinatumomab could help children and young people in this situation. Blinatumomab (MT103) is type of monoclonal antibody. It targets a protein called CD19 that is often found on leukaemia cells.
People in this trial had blinatumomab continuously into a vein for 4 weeks, and then no treatment for 2 weeks. Each 6 week period is called one cycle of treatment.
There were two parts to this study – phase 1 and phase 2.
In phase 1, the research team wanted to find the best dose of blinatumomab to give to people under 18 years old.
In phase 2, they wanted to find out how well blinatumomab worked for children and teenagers with ALL. It was for people with leukaemia that had not responded to or had come back after other treatment
Summary of results
- a drop in red blood cells, blood clotting cells (platelets) and white blood cells
- a drop in blood potassium level, which can cause heart problems
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Ajay Vora
NIHR Clinical Research Network: Cancer